200 related articles for article (PubMed ID: 30237855)
1. The Jumonji-domain histone demethylase inhibitor JIB-04 deregulates oncogenic programs and increases DNA damage in Ewing Sarcoma, resulting in impaired cell proliferation and survival, and reduced tumor growth.
Parrish JK; McCann TS; Sechler M; Sobral LM; Ren W; Jones KL; Tan AC; Jedlicka P
Oncotarget; 2018 Sep; 9(69):33110-33123. PubMed ID: 30237855
[TBL] [Abstract][Full Text] [Related]
2. KDM5A and PHF2 positively control expression of pro-metastatic genes repressed by EWS/Fli1, and promote growth and metastatic properties in Ewing sarcoma.
McCann TS; Parrish JK; Hsieh J; Sechler M; Sobral LM; Self C; Jones KL; Goodspeed A; Costello JC; Jedlicka P
Oncotarget; 2020 Oct; 11(43):3818-3831. PubMed ID: 33196691
[TBL] [Abstract][Full Text] [Related]
3. BET bromodomain inhibitors suppress EWS-FLI1-dependent transcription and the IGF1 autocrine mechanism in Ewing sarcoma.
Loganathan SN; Tang N; Fleming JT; Ma Y; Guo Y; Borinstein SC; Chiang C; Wang J
Oncotarget; 2016 Jul; 7(28):43504-43517. PubMed ID: 27259270
[TBL] [Abstract][Full Text] [Related]
4. The histone demethylase KDM3A is a microRNA-22-regulated tumor promoter in Ewing Sarcoma.
Parrish JK; Sechler M; Winn RA; Jedlicka P
Oncogene; 2015 Jan; 34(2):257-62. PubMed ID: 24362521
[TBL] [Abstract][Full Text] [Related]
5. Targeting the epigenetic readers in Ewing sarcoma inhibits the oncogenic transcription factor EWS/Fli1.
Jacques C; Lamoureux F; Baud'huin M; Rodriguez Calleja L; Quillard T; Amiaud J; Tirode F; Rédini F; Bradner JE; Heymann D; Ory B
Oncotarget; 2016 Apr; 7(17):24125-40. PubMed ID: 27006472
[TBL] [Abstract][Full Text] [Related]
6. MiR-193b, downregulated in Ewing Sarcoma, targets the ErbB4 oncogene to inhibit anchorage-independent growth.
Moore C; Parrish JK; Jedlicka P
PLoS One; 2017; 12(5):e0178028. PubMed ID: 28542597
[TBL] [Abstract][Full Text] [Related]
7. EWS-FLI1-mediated suppression of the RAS-antagonist Sprouty 1 (SPRY1) confers aggressiveness to Ewing sarcoma.
Cidre-Aranaz F; Grünewald TG; Surdez D; García-García L; Carlos Lázaro J; Kirchner T; González-González L; Sastre A; García-Miguel P; López-Pérez SE; Monzón S; Delattre O; Alonso J
Oncogene; 2017 Feb; 36(6):766-776. PubMed ID: 27375017
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic opportunities in Ewing sarcoma: EWS-FLI inhibition via LSD1 targeting.
Theisen ER; Pishas KI; Saund RS; Lessnick SL
Oncotarget; 2016 Apr; 7(14):17616-30. PubMed ID: 26848860
[TBL] [Abstract][Full Text] [Related]
9. EWS-FLI1 inhibits TNFalpha-induced NFkappaB-dependent transcription in Ewing sarcoma cells.
Lagirand-Cantaloube J; Laud K; Lilienbaum A; Tirode F; Delattre O; Auclair C; Kryszke MH
Biochem Biophys Res Commun; 2010 Sep; 399(4):705-10. PubMed ID: 20691659
[TBL] [Abstract][Full Text] [Related]
10. Cholecystokinin down-regulation by RNA interference impairs Ewing tumor growth.
Carrillo J; García-Aragoncillo E; Azorín D; Agra N; Sastre A; González-Mediero I; García-Miguel P; Pestaña A; Gallego S; Segura D; Alonso J
Clin Cancer Res; 2007 Apr; 13(8):2429-40. PubMed ID: 17438102
[TBL] [Abstract][Full Text] [Related]
11. Functional, chemical genomic, and super-enhancer screening identify sensitivity to cyclin D1/CDK4 pathway inhibition in Ewing sarcoma.
Kennedy AL; Vallurupalli M; Chen L; Crompton B; Cowley G; Vazquez F; Weir BA; Tsherniak A; Parasuraman S; Kim S; Alexe G; Stegmaier K
Oncotarget; 2015 Oct; 6(30):30178-93. PubMed ID: 26337082
[TBL] [Abstract][Full Text] [Related]
12. Overexpression of HOX genes is prevalent in Ewing sarcoma and is associated with altered epigenetic regulation of developmental transcription programs.
Svoboda LK; Harris A; Bailey NJ; Schwentner R; Tomazou E; von Levetzow C; Magnuson B; Ljungman M; Kovar H; Lawlor ER
Epigenetics; 2014 Dec; 9(12):1613-25. PubMed ID: 25625846
[TBL] [Abstract][Full Text] [Related]
13. Slit2 signaling stimulates Ewing sarcoma growth.
Suvarna K; Jayabal P; Ma X; Shiio Y
Genes Cancer; 2022; 13():88-99. PubMed ID: 36533189
[TBL] [Abstract][Full Text] [Related]
14. The EWS/FLI1 oncogenic protein inhibits expression of the Wnt inhibitor DICKKOPF-1 gene and antagonizes beta-catenin/TCF-mediated transcription.
Navarro D; Agra N; Pestaña A; Alonso J; González-Sancho JM
Carcinogenesis; 2010 Mar; 31(3):394-401. PubMed ID: 20019092
[TBL] [Abstract][Full Text] [Related]
15. The orphan nuclear receptor DAX1 is up-regulated by the EWS/FLI1 oncoprotein and is highly expressed in Ewing tumors.
Mendiola M; Carrillo J; García E; Lalli E; Hernández T; de Alava E; Tirode F; Delattre O; García-Miguel P; López-Barea F; Pestaña A; Alonso J
Int J Cancer; 2006 Mar; 118(6):1381-9. PubMed ID: 16206264
[TBL] [Abstract][Full Text] [Related]
16. Blocking the road, stopping the engine or killing the driver? Advances in targeting EWS/FLI-1 fusion in Ewing sarcoma as novel therapy.
Kovar H
Expert Opin Ther Targets; 2014 Nov; 18(11):1315-28. PubMed ID: 25162919
[TBL] [Abstract][Full Text] [Related]
17. EWS-FLI1, EWS-ERG, and EWS-ETV1 oncoproteins of Ewing tumor family all suppress transcription of transforming growth factor beta type II receptor gene.
Im YH; Kim HT; Lee C; Poulin D; Welford S; Sorensen PH; Denny CT; Kim SJ
Cancer Res; 2000 Mar; 60(6):1536-40. PubMed ID: 10749119
[TBL] [Abstract][Full Text] [Related]
18. The histone demethylase KDM3A, and its downstream target MCAM, promote Ewing Sarcoma cell migration and metastasis.
Sechler M; Parrish JK; Birks DK; Jedlicka P
Oncogene; 2017 Jul; 36(29):4150-4160. PubMed ID: 28319067
[TBL] [Abstract][Full Text] [Related]
19. Targeting the EWS-ETS transcriptional program by BET bromodomain inhibition in Ewing sarcoma.
Hensel T; Giorgi C; Schmidt O; Calzada-Wack J; Neff F; Buch T; Niggli FK; Schäfer BW; Burdach S; Richter GH
Oncotarget; 2016 Jan; 7(2):1451-63. PubMed ID: 26623725
[TBL] [Abstract][Full Text] [Related]
20. Variable expression of PIK3R3 and PTEN in Ewing Sarcoma impacts oncogenic phenotypes.
Niemeyer BF; Parrish JK; Spoelstra NS; Joyal T; Richer JK; Jedlicka P
PLoS One; 2015; 10(1):e0116895. PubMed ID: 25603314
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
